In our in vitro experiments, we found a stronger decrease of PD-1 induced by ATP-pocket-binding TKIs compared to asciminib, which might be advantageous because reduced PD-1-expression is thought to promote sustained DMR in CML [3]. This evidence concerns the gene PDCD1 and chronic myelogenous leukemia, BCR-ABL1 positive.